Synektik Group is a leading provider of advanced radiopharmaceutical products, IT solutions, innovative medical devices, and measurement and service offerings for medical institutions. They specialize in minimally invasive surgery, diagnostic imaging, interventional diagnostics, hospital pharmacy, gynecology, oncology, neurology, radiopharmacy, radiotherapy, robotics, and IT support and solutions.
3 signals in the last 90 days.
The order this company entered each market — oldest to newest
GPW Map: Tauron, Bogdanka, Dino, Synektik and Amica in focus
GPW Map: Tauron, Bogdanka, Dino, Synektik and Amica in focus
Sign up to see the full signal feed
How Synektik's international expansion compares to its competitors
SynektikYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 SynektikYou | 3 | 3 | -100% | 3 | 12 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Key updates for Warsaw Stock Exchange session include foreign investor interest, Pure Biologics payment delay, Synektik share sale, German election impact, and developments in real estate and energy sectors.
Tauron's dividend declaration boosts energy sector. Coal stocks rise. Dino and Amica fall post-results. Synektik's spin-off Syn2bio approved for trading.
Syn2bio, spun off from Synektik, debuts on Warsaw Stock Exchange on April 15, offering investors a cardiac marker project developed over 15 years with over 100 million PLN invested, now in phase 3 clinical trials.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Synektik's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
